Endostatin's endpoints-Deciphering the endostatin antiangiogenic pathway.
Up until now, the precise mechanism for endostatin's antiangiogenesis action was not known. In a recent report, have taken advantage of gene array and proteomic analysis to map the antiangiogenic pathways turned on by endostatin. This study resolves some of the controversies surrounding endostatin's biology, and provides a new direction to help dissect the molecular pathways involved in endostatin's selective tumor antiangiogenic effects.
Benezra
Robert
R
Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 USA. r-benezra@ski.mskcc.org
Rafii
Shahin
S
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D018955:CD36 Antigens / Q000378:metabolism; D043169:Endostatins / Q000378:metabolism*; D042783:Endothelial Cells / Q000378:metabolism*; D020869:Gene Expression Profiling; D039081:Integrin alpha5beta1 / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D010766:Phosphorylation; D011971:Receptors, Immunologic; D018110:Receptors, Lipoprotein / Q000378:metabolism; D051116:Receptors, Scavenger; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D018955:CD36 Antigens; D043169:Endostatins; D039081:Integrin alpha5beta1; D011971:Receptors, Immunologic; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; D042461:Vascular Endothelial Growth Factor A; D040301:Vascular Endothelial Growth Factor Receptor-2